Opinion|Videos|July 12, 2024
Key Takeaways on Recent Data from PERSEUS
Author(s)Cesar Rodriguez, MD, Frits van Rhee, MD, PhD
Frits van Rhee, MD, PhD, and Cesar Rodriguez, MD, provide key takeaways on findings from the PERSEUS trial and discuss unmet needs that remain in the multiple myeloma treatment landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What are your key takeaways on findings from the PERSEUS trial?
- What are some remaining unanswered questions from this trial?
- What will be important to evaluate in future analyses and research?
Advertisement
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
Matthew J. Frigault, MD, and Adam D. Cohen, MD, discuss guidelines, 5-year data, sequencing, and referral practice for cellular therapy in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
2
Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC
3
Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?
4
Breast Cancer Locator Noninferior to Wire Localization for Lumpectomy Margins
5